-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)
-
-
-
-
-
-
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) Tops Q4 EPS by 3c
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) PT Raised to $30 at RBC Capital
-
-
-
-
-
-
-
Ocular Therapeutix completes enrollment in wet AMD drug trial
-
-
-
-
-
-
-
Chardan Capital Markets Starts Ocular Therapeutix (OCUL) at Buy
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)
-
430,614 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

